{
  "$schema": "folio-library-document/v1",
  "id": "10665-69384",
  "title": "Preparing for the introduction of HPV vaccines : policy and programme guidance for countries",
  "variant": "pdf",
  "pages": 27,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "Introduction",
      "number": null,
      "page": 7,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-000-introduction"
    },
    {
      "level": 1,
      "title": "Cervical cancer and HPV infection",
      "number": null,
      "page": 7,
      "pageLabel": "1",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-001-cervical-cancer-and-hpv-infection"
    },
    {
      "level": 1,
      "title": "Vaccines against HPV V V",
      "number": null,
      "page": 9,
      "pageLabel": "3",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-002-vaccines-against-hpv-v-v"
    },
    {
      "level": 1,
      "title": "Target populations for HPV immunization",
      "number": null,
      "page": 10,
      "pageLabel": "4",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-003-target-populations-for-hpv-immunization"
    },
    {
      "level": 1,
      "title": "Innovative features of HPV vaccines",
      "number": null,
      "page": 12,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-004-innovative-features-of-hpv-vaccines"
    },
    {
      "level": 1,
      "title": "A unique opportunity",
      "number": null,
      "page": 12,
      "pageLabel": "6",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-005-a-unique-opportunity"
    },
    {
      "level": 1,
      "title": "An expensive product",
      "number": null,
      "page": 14,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-006-an-expensive-product"
    },
    {
      "level": 1,
      "title": "Introduction challenges",
      "number": null,
      "page": 14,
      "pageLabel": "8",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-007-introduction-challenges"
    },
    {
      "level": 1,
      "title": "Not business as usual",
      "number": null,
      "page": 15,
      "pageLabel": "9",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-008-not-business-as-usual"
    },
    {
      "level": 1,
      "title": "Advocacy, information and communication",
      "number": null,
      "page": 16,
      "pageLabel": "10",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-009-advocacy-information-and-communication"
    },
    {
      "level": 1,
      "title": "Action points",
      "number": null,
      "page": 17,
      "pageLabel": "11",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-010-action-points"
    },
    {
      "level": 1,
      "title": "Service delivery",
      "number": null,
      "page": 19,
      "pageLabel": "13",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-011-service-delivery"
    },
    {
      "level": 1,
      "title": "Reaching target populations",
      "number": null,
      "page": 19,
      "pageLabel": "13",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-012-reaching-target-populations"
    },
    {
      "level": 1,
      "title": "Partnerships between programmes",
      "number": null,
      "page": 20,
      "pageLabel": "14",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-013-partnerships-between-programmes"
    },
    {
      "level": 1,
      "title": "Monitoring and evaluation",
      "number": null,
      "page": 21,
      "pageLabel": "15",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-014-monitoring-and-evaluation"
    },
    {
      "level": 1,
      "title": "Action points",
      "number": null,
      "page": 21,
      "pageLabel": "15",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-015-action-points"
    },
    {
      "level": 1,
      "title": "Stewardship and ﬁ nancing",
      "number": null,
      "page": 23,
      "pageLabel": "17",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-016-stewardship-and-ﬁ-nancing"
    },
    {
      "level": 1,
      "title": "Action points",
      "number": null,
      "page": 24,
      "pageLabel": "18",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-017-action-points"
    },
    {
      "level": 1,
      "title": "Epilogue",
      "number": null,
      "page": 26,
      "pageLabel": "20",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-018-epilogue"
    },
    {
      "level": 1,
      "title": "Additional resources",
      "number": null,
      "page": 27,
      "pageLabel": "21",
      "confidence": 0.9,
      "evidence": [
        "contents",
        "body",
        "style"
      ],
      "source": "inferred",
      "section": "sec-019-additional-resources"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 7,
      "labelStart": "I",
      "labelEnd": "1",
      "words": 755,
      "summary": {
        "text": "The front matter of WHO's 2006 guidance 'Preparing for the introduction of HPV vaccines: policy and programme guidance for countries', with copyright, disclaimers and a contents list. It notes that the content draws on a March 2006 technical consultation in Montreux on sexual and reproductive health programmes and HPV vaccines and lists the participating experts. The acknowledgements name the UNFPA and WHO departments involved and say the note aims to alert stakeholders in several health programmes to key issues.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccines",
          "heading": false
        },
        {
          "term": "felicity cutts",
          "heading": false
        },
        {
          "term": "dale huntington",
          "heading": false
        },
        {
          "term": "nathalie broutet",
          "heading": false
        },
        {
          "term": "peter hall",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        }
      ],
      "extract": "Preparing for the introduction of HPV vaccines: policy and programme guidance for countries Preparing for the introduction of HPV vaccines: policy and programme guidance for countries © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax:",
      "extractCut": true,
      "blocks": [
        "library/10665-69384/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-introduction",
      "number": null,
      "title": "Introduction",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 7,
      "labelStart": "1",
      "labelEnd": "1",
      "words": 41,
      "summary": {
        "text": "Explains that the guidance highlights how immunization, sexual and reproductive health and cancer control programmes can prepare for national HPV vaccine introduction under the Global Immunization Vision and Strategy.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "trol",
          "heading": false
        },
        {
          "term": "immunization",
          "heading": false
        },
        {
          "term": "cer",
          "heading": false
        }
      ],
      "extract": "cer. In particular, it highlights the contributions that national immunization programmes, sexual and reproductive health programmes, and cancer con- trol programmes can make in preparing for national introduction of the vaccines in the context of the Global Immunization Vision and Strategy.",
      "extractCut": false
    },
    {
      "id": "sec-001-cervical-cancer-and-hpv-infection",
      "number": null,
      "title": "Cervical cancer and HPV infection",
      "level": 1,
      "pageStart": 7,
      "pageEnd": 9,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 723,
      "summary": {
        "text": "Describes cervical cancer as the second most common cancer in women worldwide, with about 500 000 cases and 250 000 deaths a year, mostly in low-income countries, and nearly all linked to HPV infection, especially types 16 and 18. It explains that HPV infection usually clears but can persist and lead to precancerous lesions over decades, which screening can detect, and that visual inspection with acetic acid and cryotherapy offer a simpler approach for low-resource settings. It also notes the 2005 World Health Assembly resolution on cancer prevention and control and early vaccine trial results showing near-complete protection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": true
        },
        {
          "term": "hpv infection",
          "heading": true
        },
        {
          "term": "against cervical",
          "heading": false
        },
        {
          "term": "cancer cases",
          "heading": false
        },
        {
          "term": "precancerous lesions",
          "heading": false
        },
        {
          "term": "persistent hpv",
          "heading": false
        },
        {
          "term": "common cancer",
          "heading": false
        },
        {
          "term": "hpv types",
          "heading": false
        }
      ],
      "extract": "infection Cancer of the cervix is the second most common cancer in women worldwide, with about 500 000 new cases and 250 000 deaths each year. Almost 80% of cases occur in low-income countries, where cervical cancer is the most common cancer in women. Virtually all cervical cancer cases (99%) are linked to genital infection with human papillomavirus (HPV), which is the most common viral infection of the reproductive",
      "extractCut": true
    },
    {
      "id": "sec-002-vaccines-against-hpv-v-v",
      "number": null,
      "title": "Vaccines against HPV V V",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 10,
      "labelStart": "3",
      "labelEnd": "4",
      "words": 198,
      "summary": {
        "text": "Explains that HPV vaccines are made of non-infectious virus-like particles and that two prophylactic vaccines have shown excellent efficacy against precancerous lesions linked to the vaccine types, with the quadrivalent vaccine also preventing genital warts. It notes the vaccines are expected to prevent about 70% of cervical cancers in HPV-naive women and that questions on long-term efficacy, boosters and special populations are still being studied.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccines",
          "heading": true
        },
        {
          "term": "efﬁ cacy",
          "heading": false
        },
        {
          "term": "immunogenicity",
          "heading": false
        },
        {
          "term": "particles",
          "heading": false
        },
        {
          "term": "genotypes",
          "heading": false
        },
        {
          "term": "contain",
          "heading": false
        },
        {
          "term": "women",
          "heading": false
        }
      ],
      "extract": "HPV vaccines contain the major capsid L1 proteins, which self-assemble into virus-like particles (VLP) resembling HPV. These particles do not contain viral genetic material and thus are unable to multiply, which means they are non-infectious. Two prophy- lactic HPV vaccines have shown excellent efﬁ cacy precursor lesions related to the vaccine genotypes. For the quadrivalent vaccine, protection against genital warts",
      "extractCut": true
    },
    {
      "id": "sec-003-target-populations-for-hpv-immunization",
      "number": null,
      "title": "Target populations for HPV immunization",
      "level": 1,
      "pageStart": 10,
      "pageEnd": 12,
      "labelStart": "4",
      "labelEnd": "6",
      "words": 643,
      "summary": {
        "text": "Argues that HPV vaccines should be given before sexual debut and notes they will likely be licensed for girls and women aged 9–26, with stronger immune responses in young adolescents and possible catch-up vaccination. It describes the expected availability of Cervarix and Gardasil and the uncertain benefit of vaccinating males, younger children, people with HIV and pregnant women. It links vaccine introduction to WHO's reproductive health strategy and its call to use existing services as entry points.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv",
          "heading": true
        },
        {
          "term": "hpv vaccines",
          "heading": false
        },
        {
          "term": "hpv types",
          "heading": false
        },
        {
          "term": "sexual debut",
          "heading": false
        },
        {
          "term": "popula tion",
          "heading": false
        },
        {
          "term": "immunization",
          "heading": true
        },
        {
          "term": "pregnant women",
          "heading": false
        },
        {
          "term": "both vaccines",
          "heading": false
        }
      ],
      "extract": "HPV immunization In deﬁ ning the target population for immunization, a key consideration is that HPV infection is sexually transmitted and is usually acquired within the ﬁ rst few years following sexual debut. Ideally, therefore, the vaccine should be administered before sexual debut, i.e. before any risk of exposure to HPV. Current indications suggest that, initially, the HPV vaccines will be licensed for use in",
      "extractCut": true
    },
    {
      "id": "sec-004-innovative-features-of-hpv-vaccines",
      "number": null,
      "title": "Innovative features of HPV vaccines",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 12,
      "labelStart": "6",
      "labelEnd": "6",
      "words": 55,
      "summary": {
        "text": "Notes that HPV vaccines could strengthen links between health services and prevent a common cancer as well as genital dysplasia and warts on a large scale, and introduces their key features.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccines",
          "heading": true
        },
        {
          "term": "features",
          "heading": true
        },
        {
          "term": "dysplasia",
          "heading": false
        }
      ],
      "extract": "HPV vaccines HPV vaccines have the potential to strengthen interactions among different health services and to provide a new way of preventing a common cancer on a very large scale, as well as reducing the more widespread burden of genital dysplasia and warts. Some of the key features of the vaccines are dis- cussed below.",
      "extractCut": false
    },
    {
      "id": "sec-005-a-unique-opportunity",
      "number": null,
      "title": "A unique opportunity",
      "level": 1,
      "pageStart": 12,
      "pageEnd": 14,
      "labelStart": "6",
      "labelEnd": "8",
      "words": 692,
      "summary": {
        "text": "Explains that HPV vaccines need new delivery approaches because they target adolescents rather than infants, involve many stakeholders and bring immunization programmes into the sensitive area of sexual health. It describes the Global Immunization Vision and Strategy's aim to extend immunization to other age groups and the hard priority choices cancer programmes face. It sees the vaccines as a chance to promote delayed sexual debut and condom use, which will depend on strong partnerships between programmes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccines",
          "heading": false
        },
        {
          "term": "immunization vision",
          "heading": false
        },
        {
          "term": "global immunization",
          "heading": false
        },
        {
          "term": "immunization programmes",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "intro duction",
          "heading": false
        },
        {
          "term": "diseases immunization",
          "heading": false
        },
        {
          "term": "national immunization",
          "heading": false
        }
      ],
      "extract": "Vaccines against HPV have several features that require special consideration. Their use requires new approaches to programme delivery; the target population is different from that usually addressed by national immunization programmes; multiple stakeholders need to be involved in advocacy and social communication; and the best combination of vaccination and screening for cervical cancer programmes remains unclear.",
      "extractCut": true
    },
    {
      "id": "sec-006-an-expensive-product",
      "number": null,
      "title": "An expensive product",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 14,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 203,
      "summary": {
        "text": "Notes that HPV vaccines are likely to cost much more than traditional EPI vaccines and that international financing, for example through GAVI, is being discussed. It warns that cost should not be the only criterion and that private-sector introduction among affluent groups could widen health inequities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccines",
          "heading": false
        },
        {
          "term": "advocacy",
          "heading": false
        },
        {
          "term": "private",
          "heading": false
        },
        {
          "term": "introduction",
          "heading": false
        },
        {
          "term": "settings",
          "heading": false
        },
        {
          "term": "public",
          "heading": false
        }
      ],
      "extract": "Although the price of HPV vaccines for developing countries is not yet known, it is likely to be sub- stantially higher than the traditional EPI vaccines, at least initially, even with differential pricing between developed- and developing-country markets. Discussions are under way to obtain access to international ﬁ nancing mechanisms (e.g. through the Global Alliance for Vaccines and Immuniza- tion – GAVI), which",
      "extractCut": true
    },
    {
      "id": "sec-007-introduction-challenges",
      "number": null,
      "title": "Introduction challenges",
      "level": 1,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 204,
      "summary": {
        "text": "Stresses that HPV vaccine delivery must be affordable, feasible and culturally acceptable and that backlash against sexual and reproductive health programmes must be avoided. It calls for clear complementary messages on delaying sex, condom use, HIV prevention and screening, and hopes the vaccine will spur cervical screening where it is lacking.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "cancer screening",
          "heading": false
        },
        {
          "term": "cancer control",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        },
        {
          "term": "hpv",
          "heading": false
        },
        {
          "term": "health programmes",
          "heading": false
        },
        {
          "term": "sexual",
          "heading": false
        }
      ],
      "extract": "The service delivery strategy and promotion of HPV vaccines will need to be based on country-spe- ciﬁ c considerations of what is affordable, feasible and culturally acceptable. Vaccinating young girls against cancer, and other genital diseases, caused by a sexually transmitted infection may be a sensi- tive issue in some countries and cultural settings. It will be essential to avoid a harmful backlash against",
      "extractCut": true
    },
    {
      "id": "sec-008-not-business-as-usual",
      "number": null,
      "title": "Not business as usual",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 87,
      "summary": {
        "text": "Notes that HPV vaccines will require national programmes to cooperate in new ways, including with the private sector, and calls for international partnerships to shorten the delay before developing countries gain affordable access.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "usual",
          "heading": true
        },
        {
          "term": "concert",
          "heading": false
        },
        {
          "term": "negotiated",
          "heading": false
        }
      ],
      "extract": "The unique features and characteristics of the HPV vaccines mean that all the concerned programmes in each country will be challenged to ﬁ nd new ways of working together. Moreover, as mentioned above, public programmes will need to act in concert with the private sector. At international level, partnerships need to be established now to try to reduce the usual lag time between formal registration and availability",
      "extractCut": true
    },
    {
      "id": "sec-009-advocacy-information-and-communication",
      "number": null,
      "title": "Advocacy, information and communication",
      "level": 1,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 712,
      "summary": {
        "text": "Discusses the challenges and opportunities of advocacy, information and communication on HPV vaccination, stressing balanced messages and presentation of the vaccines within a broader strategy for cervical cancer prevention and sexual and reproductive health. It lists key messages: HPV causes over 99% of cervical cancers, is very common and highly transmissible, usually causes no symptoms, and the vaccines work best before sexual debut but do not protect against all types or other STIs, so screening must continue. It advises adapting messages to local sociocultural norms, avoiding backlash linked to sexual transmission, including boys in messaging, and explaining clearly what the vaccine can and cannot do.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccines",
          "heading": false
        },
        {
          "term": "hpv vaccination",
          "heading": false
        },
        {
          "term": "hpv types",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "sexual debut",
          "heading": false
        },
        {
          "term": "protect against",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        },
        {
          "term": "ing",
          "heading": false
        }
      ],
      "extract": "communication Developing advocacy, information and commu- nication programmes related to HPV vaccination, for multiple stakeholders and audiences, presents speciﬁ c challenges and opportunities. One chal- lenge is to produce a balanced and informative public education and communication programme about HPV, cervical cancer, and other HPV-related cancers and diseases, and to explain the beneﬁ ts and limitations of the",
      "extractCut": true
    },
    {
      "id": "sec-010-action-points",
      "number": null,
      "title": "Action points",
      "level": 1,
      "pageStart": 17,
      "pageEnd": 19,
      "labelStart": "11",
      "labelEnd": "13",
      "words": 665,
      "summary": {
        "text": "Lists action points on advocacy, information and communication, such as gathering country data on cancer burden and HPV strains, tailoring communication strategies to stakeholders, decision-makers and communities, and basing health promotion on local needs. It also covers developing materials and training for health workers and addressing financing questions such as insurance coverage. It urges using HPV vaccination to strengthen existing programmes for adolescents, such as school-based education on sexual health, nutrition, tobacco and HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccine",
          "heading": false
        },
        {
          "term": "intro duction",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "sexual debut",
          "heading": false
        },
        {
          "term": "advocacy groups",
          "heading": false
        },
        {
          "term": "cancer control",
          "heading": false
        },
        {
          "term": "country-speciﬁ",
          "heading": false
        },
        {
          "term": "health programme",
          "heading": false
        }
      ],
      "extract": "Key actions related to advocacy, information and communication include the following: • Interaction between those responsible for advocacy, service delivery and stewardship is important, especially to generate the evidence and country-speciﬁ c information (e.g. on cervi- cal cancer burden, HPV strains circulating in the country, age of sexual debut) needed to support policy and programmes (see section on Stew-",
      "extractCut": true
    },
    {
      "id": "sec-011-service-delivery",
      "number": null,
      "title": "Service delivery",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 19,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-012-reaching-target-populations",
      "number": null,
      "title": "Reaching target populations",
      "level": 1,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "13",
      "labelEnd": "14",
      "words": 903,
      "summary": {
        "text": "Describes the likely target populations for HPV vaccination: a primary group of girls aged 9–13, before sexual debut, and a secondary catch-up group of young women aged 14–26 who were not previously vaccinated. It weighs delivery options for the primary group, including school-based programmes, EPI or tetanus campaigns and community-based adolescent sexual and reproductive health programmes for out-of-school girls, noting limits such as school drop-out, cold-chain and staff skills. It also explains how sexual and reproductive health services can spread information to older women, stresses that screening must continue for vaccinated and older women, and warns against stand-alone vaccine delivery.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccine",
          "heading": false
        },
        {
          "term": "hpv vaccination",
          "heading": false
        },
        {
          "term": "hpv immunization",
          "heading": false
        },
        {
          "term": "out-of-school youth",
          "heading": false
        },
        {
          "term": "target",
          "heading": true
        },
        {
          "term": "sexual debut",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "pro grammes",
          "heading": false
        }
      ],
      "extract": "populations The vaccine licences will probably establish an age range of 9–26 years for the target population. This age range will need to be subdivided into two cat- egories: the primary group and the catch-up group. Primary target population This will most likely be girls aged 9–13 years, the intention being to reach them prior to sexual debut. Each country will need to identify the most con- venient and effective",
      "extractCut": true
    },
    {
      "id": "sec-013-partnerships-between-programmes",
      "number": null,
      "title": "Partnerships between programmes",
      "level": 1,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 165,
      "summary": {
        "text": "Recommends building HPV vaccine delivery on existing structures such as the cold chain, with the immunization programme likely leading in partnership with sexual and reproductive health, adolescent health, cancer control and HIV programmes. It also calls for links with education services, civil society and the private sector.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vaccine",
          "heading": false
        },
        {
          "term": "partnerships",
          "heading": true
        },
        {
          "term": "programmes",
          "heading": true
        },
        {
          "term": "delivery",
          "heading": false
        },
        {
          "term": "countries",
          "heading": false
        },
        {
          "term": "services",
          "heading": false
        }
      ],
      "extract": "programmes Programme approaches will need to be planned and organized, making the most cost-efﬁ cient use of existing or, where necessary, strengthened services. HPV vaccine delivery should be built on structures already in place at the national level, for example, the vaccine cold chain infrastruc- ture. This will maximize cost-efﬁ ciency and avoid wastage and duplication, which countries can ill afford. While it",
      "extractCut": true
    },
    {
      "id": "sec-014-monitoring-and-evaluation",
      "number": null,
      "title": "Monitoring and evaluation",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 294,
      "summary": {
        "text": "Advises planning early for monitoring and evaluation, using routine immunization surveillance for process indicators and tracking earlier outcomes such as genital warts and precancerous lesions. It also calls for adverse event monitoring that captures HIV status and pregnancy, use of cancer registries or proxies, and private-sector cooperation on reporting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "monitoring",
          "heading": true
        },
        {
          "term": "adverse events",
          "heading": false
        },
        {
          "term": "pilot studies",
          "heading": false
        },
        {
          "term": "vaccine",
          "heading": false
        },
        {
          "term": "hpv",
          "heading": false
        },
        {
          "term": "surveillance",
          "heading": false
        },
        {
          "term": "observed",
          "heading": false
        }
      ],
      "extract": "Although the construction of an effective monitoring and evaluation system is a “downstream” activity, it is important during the preparatory stage to con- sider how to assess process and impact. Process indicators will have to be measured through routine national immunization programme surveillance. The impact on genital warts (with the quadrivalent vaccine) or on abnormalities detected on screen- ing – such as",
      "extractCut": true
    },
    {
      "id": "sec-015-action-points",
      "number": null,
      "title": "Action points",
      "level": 1,
      "pageStart": 21,
      "pageEnd": 23,
      "labelStart": "15",
      "labelEnd": "17",
      "words": 324,
      "summary": {
        "text": "Lists action points for national programmes on service delivery, such as linking stakeholders, defining the primary target group, addressing sociocultural barriers, checking school attendance and updating cervical cancer strategies. It also calls for comprehensive cervical cancer prevention including screening, treatment, vaccination and monitoring of effectiveness.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv vac",
          "heading": false
        },
        {
          "term": "hpv vaccine",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "vac cines",
          "heading": false
        },
        {
          "term": "pro grammes",
          "heading": false
        },
        {
          "term": "national cervical",
          "heading": false
        },
        {
          "term": "cancer control",
          "heading": false
        },
        {
          "term": "adolescent sexual",
          "heading": false
        }
      ],
      "extract": "National programmes will need to undertake the following actions: • Develop links between the many different imple- menting stakeholders. • Deﬁ ne the primary target population, taking into account the most convenient access points, and the earliest age of sexual debut. • Address sociocultural barriers to vaccination of young adolescents. • Determine school attendance rates for the 9–13-year age group. • Update",
      "extractCut": true
    },
    {
      "id": "sec-016-stewardship-and-ﬁ-nancing",
      "number": null,
      "title": "Stewardship and ﬁ nancing",
      "level": 1,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 800,
      "summary": {
        "text": "Stresses that strengthening health systems and financing HPV vaccine purchase must be high priorities, with some decisions taken at global or higher government levels. It discusses the need for epidemiological data, demand forecasting and lessons from hepatitis B vaccine introduction, and the importance of international funding through GAVI, UNICEF and the PAHO Revolving Fund to expand supply and secure lower prices. It also covers government oversight of private-sector introduction, such as reporting of adverse events and post-marketing surveillance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "nancing",
          "heading": true
        },
        {
          "term": "hpv vaccines",
          "heading": false
        },
        {
          "term": "hpv vac",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "low-resource settings",
          "heading": false
        },
        {
          "term": "cancer control",
          "heading": false
        },
        {
          "term": "policy decisions",
          "heading": false
        },
        {
          "term": "national immunization",
          "heading": false
        }
      ],
      "extract": "health system and purchasing HPV vaccines, both internationally and within national health budgets, must be a high priority. Financing for the introduc- tion of HPV vaccine will need to be approached as part of an overall strategy involving a number of partners, both globally and within individual countries, and be part of a general scaling-up of resources to strengthen health systems. Some of the necessary ﬁ",
      "extractCut": true
    },
    {
      "id": "sec-017-action-points",
      "number": null,
      "title": "Action points",
      "level": 1,
      "pageStart": 24,
      "pageEnd": 26,
      "labelStart": "18",
      "labelEnd": "20",
      "words": 274,
      "summary": {
        "text": "Lists action points on stewardship and financing for introducing HPV vaccines, including a national HPV vaccine working group linking health programmes, civil society and the private sector, and country models to forecast demand, costs and coverage as the basis for a business case. It also calls on sexual and reproductive health programmes to help prepare funding applications to GAVI and notes that countries not eligible for GAVI support can seek technical help from WHO and UNFPA.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hpv",
          "heading": false
        },
        {
          "term": "nancial",
          "heading": false
        },
        {
          "term": "nancing",
          "heading": false
        },
        {
          "term": "gavi",
          "heading": false
        },
        {
          "term": "reproductive health",
          "heading": false
        },
        {
          "term": "funds",
          "heading": false
        },
        {
          "term": "cervical",
          "heading": false
        },
        {
          "term": "cancer",
          "heading": false
        }
      ],
      "extract": "In the area of stewardship and ﬁ nancing, the fol- lowing actions will need to be undertaken. • A broad range of stakeholders should be involved in developing a strategy for a com- prehensive and workable introduction of HPV vaccines. A national HPV vaccine working group should be established in each country to set up coordination mechanisms between health programmes, civil society and private sector. This could be",
      "extractCut": true
    },
    {
      "id": "sec-018-epilogue",
      "number": null,
      "title": "Epilogue",
      "level": 1,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 345,
      "summary": {
        "text": "Concludes that each country will decide nationally on introducing HPV vaccines, which should be placed within integrated, comprehensive cervical cancer control and delivered through strong partnerships, with attention to equity so that poorer women are reached. A note added in proof reports the US FDA's June 2006 approval of the quadrivalent vaccine Gardasil for girls and women aged 9–26 and lists the cancers, warts and precancerous lesions it is intended to prevent.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "intraepithelial neoplasia",
          "heading": false
        },
        {
          "term": "cervical intraepithelial",
          "heading": false
        },
        {
          "term": "hpv vaccine",
          "heading": false
        },
        {
          "term": "cervical cancer",
          "heading": false
        },
        {
          "term": "human papillomavirus",
          "heading": false
        },
        {
          "term": "grade",
          "heading": false
        },
        {
          "term": "universal access",
          "heading": false
        },
        {
          "term": "fda",
          "heading": false
        }
      ],
      "extract": "Ultimately, the decision on whether and when to introduce an HPV vaccine will depend on national policy in each country. An overarching consid- eration is the importance of positioning the HPV vaccine within a comprehensive, integrated service delivery structure. Because this vaccine “ﬁ ts” in several different programmes, effective partner- ships will be key to any successful introduction programme. Moreover,",
      "extractCut": true
    },
    {
      "id": "sec-019-additional-resources",
      "number": null,
      "title": "Additional resources",
      "level": 1,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 11,
      "summary": {
        "text": "Lists web links to UNFPA, WHO, GIVS and GAVI as additional resources.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "UNFPA http://www.unfpa.org/ WHO http://www.who.int/en/ http://www.who.int/reproductive-health http://www.who.int/cancer/en/ http://www.who.int/reproductive-health/pages_resources/listing_cancer.en.html GIVS http://www.who.int/immunization/givs/en/index.html GAVI http://www.gavialliance.org/",
      "extractCut": false
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 24,
      "items": [
        "p4: pdf-labels IV, printed ii",
        "p5: pdf-labels V, printed iii",
        "p6: pdf-labels Sec1:6, printed iv",
        "p7: pdf-labels Sec2:1, printed 1, contents 1",
        "p8: pdf-labels Sec2:2, printed 2",
        "p9: pdf-labels Sec2:3, printed 3, contents 3",
        "p10: pdf-labels Sec2:4, printed 4, contents 4",
        "p11: pdf-labels Sec2:5, printed 5",
        "p12: pdf-labels Sec2:6, printed 6, contents 6",
        "p13: pdf-labels Sec2:7, printed 7",
        "p14: pdf-labels Sec2:8, printed 8, contents 8",
        "p15: pdf-labels Sec2:9, printed 9, contents 9",
        "p16: pdf-labels Sec2:10, printed 10, contents 10",
        "p17: pdf-labels Sec2:11, printed 11, contents 11",
        "p18: pdf-labels Sec2:12, printed 12",
        "p19: pdf-labels Sec2:13, printed 13, contents 13",
        "p20: pdf-labels Sec2:14, printed 14, contents 14",
        "p21: pdf-labels Sec2:15, printed 15, contents 15",
        "p22: pdf-labels Sec2:16, printed 16",
        "p23: pdf-labels Sec2:17, printed 17, contents 17",
        "p24: pdf-labels Sec2:18, printed 18, contents 18",
        "p25: pdf-labels Sec2:19, printed 19",
        "p26: pdf-labels Sec2:20, printed 20, contents 20",
        "p27: pdf-labels Sec2:21, printed 21, contents 21"
      ]
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "hpv vaccines",
      "heading": true
    },
    {
      "term": "hpv immunization",
      "heading": true
    },
    {
      "term": "hpv vaccination",
      "heading": false
    },
    {
      "term": "cervical cancer",
      "heading": true
    },
    {
      "term": "hpv vac",
      "heading": false
    },
    {
      "term": "against hpv",
      "heading": true
    },
    {
      "term": "hpv infection",
      "heading": true
    },
    {
      "term": "different hpv",
      "heading": true
    },
    {
      "term": "hpv genotypes",
      "heading": false
    },
    {
      "term": "hpv types",
      "heading": true
    },
    {
      "term": "preventing hpv",
      "heading": false
    },
    {
      "term": "hpv testing",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "I",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "II",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "III",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 7,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 8,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 9,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 11,
      "label": "5",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 12,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "7",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 14,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "12",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 19,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "16",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 23,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "19",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 26,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    }
  ],
  "figures": [
    {
      "kind": "figure",
      "number": "1",
      "title": "Prevalence of HPV infection, precancerous lesions and cervical cancer by age of women",
      "page": 8,
      "pageLabel": "2",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "figure",
      "number": "2",
      "title": "Prevalence (%) of different HPV types among women with cancer, by region",
      "page": 9,
      "pageLabel": "3",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p009",
      "file": "figures/vfig-p009.webp",
      "page": 9,
      "shows": [
        "Figure 2"
      ],
      "narratives": {
        "en": "Page render with Figure 2, 'Prevalence (%) of different HPV types among women with cancer, by region': a stacked bar chart for Central/South America, North America/Europe, Northern Africa and South Asia, with segments for HPV types 16, 18, 45, 31, 33, 52, 58 and others. HPV 16 is the largest share in every region (57, 70, 68 and 53%), followed by HPV 18 (13, 15, 17 and 26%). The page also has text on HPV vaccines.",
        "ar": "صفحة مصيّرة تتضمن الشكل 2، 'Prevalence (%) of different HPV types among women with cancer, by region': مخطط أعمدة مكدسة لأمريكا الوسطى/الجنوبية، وأمريكا الشمالية/أوروبا، وشمال أفريقيا، وجنوب آسيا، بأجزاء لأنماط فيروس الورم الحليمي البشري 16 و18 و45 و31 و33 و52 و58 وغيرها. يمثل النمط 16 الحصة الأكبر في كل إقليم (57 و70 و68 و53%)، يليه النمط 18 (13 و15 و17 و26%). وتتضمن الصفحة أيضًا نصًا عن لقاحات فيروس الورم الحليمي البشري.",
        "zh": "页面渲染图，含图2“Prevalence (%) of different HPV types among women with cancer, by region”：堆积条形图，涵盖中/南美洲、北美洲/欧洲、北非和南亚，分段显示人乳头瘤病毒16、18、45、31、33、52、58型及其他型。各地区中16型占比最大（57%、70%、68%和53%），其次为18型（13%、15%、17%和26%）。页面还包含关于人乳头瘤病毒疫苗的文字。",
        "es": "Representación de la página con la figura 2, «Prevalence (%) of different HPV types among women with cancer, by region»: un gráfico de barras apiladas para América Central/del Sur, América del Norte/Europa, África del Norte y Asia Meridional, con segmentos para los tipos de VPH 16, 18, 45, 31, 33, 52, 58 y otros. El VPH 16 es la mayor proporción en todas las regiones (57, 70, 68 y 53 %), seguido del VPH 18 (13, 15, 17 y 26 %). La página incluye también texto sobre las vacunas contra el VPH.",
        "fr": "Rendu de page avec la figure 2, « Prevalence (%) of different HPV types among women with cancer, by region » : un graphique à barres empilées pour l'Amérique centrale/du Sud, l'Amérique du Nord/Europe, l'Afrique du Nord et l'Asie du Sud, avec des segments pour les types de VPH 16, 18, 45, 31, 33, 52, 58 et autres. Le VPH 16 représente la plus grande part dans chaque région (57, 70, 68 et 53 %), suivi du VPH 18 (13, 15, 17 et 26 %). La page contient aussi du texte sur les vaccins anti-VPH.",
        "ru": "Изображение страницы с рисунком 2 «Prevalence (%) of different HPV types among women with cancer, by region»: столбчатая диаграмма с накоплением для Центральной/Южной Америки, Северной Америки/Европы, Северной Африки и Южной Азии с сегментами для типов ВПЧ 16, 18, 45, 31, 33, 52, 58 и прочих. ВПЧ 16 составляет наибольшую долю во всех регионах (57, 70, 68 и 53%), за ним следует ВПЧ 18 (13, 15, 17 и 26%). На странице также есть текст о вакцинах против ВПЧ."
      },
      "state": "draft"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 20,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 21,
      "note": "one level"
    },
    {
      "kind": "figures",
      "state": "partial",
      "count": 1,
      "note": "2 captioned in the text"
    },
    {
      "kind": "tables",
      "state": "not-extracted"
    },
    {
      "kind": "references",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "found",
      "count": 3
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 20,
      "note": "20 of 21 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-69384"
  }
}
